Breaking Down Akeso, Inc. Financial Health: Key Insights for Investors

Born from a team of globally experienced scientists in 2012, Akeso, Inc. has rapidly translated its mission to create first-in-class and affordable therapeutic antibodies into measurable scale - listing on the Hong Kong main board in April 2020 and growing into a company with a market capitalization of HKD 107.96 billion and 921.14 million shares outstanding, driven by an ACE end-to-end platform and a diversified pipeline of over 50 innovative antibody drugs (including 24 candidates in clinical trials and 15 bispecific/multispecific programs) as it pursues a vision of global leadership, rapid clinical advancement, value-accretive partnerships, and a culture anchored in accountability, integrity, and collaboration to address unmet needs in cancer, autoimmune, inflammatory and metabolic diseases.

Akeso, Inc. (9926.HK) - Intro

• Founded: 2012 (Hong Kong)
• Listing: Main Board, HKEX, April 2020 (Stock code: 9926)
• Market capitalization (Dec 2025): HKD 107.96 billion
• Shares outstanding: 921.14 million
• Pipeline: >50 innovative antibody drugs; 24 clinical-stage candidates

Mission

• Deliver transformative antibody therapeutics to patients across oncology and immunology.
• Advance bispecific and multispecific antibody modalities and ADCs as differentiated therapeutic options.
• Translate scientific innovation into scalable, high-quality manufacturing and global commercialization.

Vision

Core Values

• Scientific Rigor - evidence-driven discovery and robust translational science.
• Patient Centricity - prioritizing unmet needs and meaningful clinical benefit.
• Innovation - platform-first development and rapid adoption of next-gen modalities (bispecifics, ADCs, RNA and cell therapies).
• Integrity & Compliance - high-quality manufacturing, regulatory excellence and ethical conduct.
• Collaboration - strategic partnerships, licensing and global commercialization alliances.

The ACE Platform - Capabilities & Strategic Advantage

• Tetrabody bispecific antibody development - proprietary formats for multi-target engagement.
• Bispecific ADCs - combining targeting precision with potent payload delivery.
• ADC technology - linker and payload expertise for optimized therapeutic index.
• RNA modalities - SiRNA and mRNA capabilities to broaden modality mix.
• Cell therapy interfaces - enabling combination strategies with biologics.

Pipeline & Clinical Footprint (Key Numbers)

• Total innovative antibody programs: >50
• Clinical-stage candidates: 24
• Bispecific / multispecific antibodies and bispecific ADCs in clinic: 15
• Therapeutic focus: oncology (majority), immunology and other high-unmet-need areas

Financial & Corporate Metrics (Selected)

Strategic Priorities Aligned to Mission & Values

• Advance clinical development of prioritized bispecifics and ADCs to registration-enabling trials.
• Leverage ACE Platform to increase hit-to-lead throughput and reduce IND timelines.
• Scale manufacturing capabilities for global supply and commercial launches.
• Pursue selective global partnerships and out-licensing to accelerate patient access.

Further reading: Exploring Akeso, Inc. Investor Profile: Who's Buying and Why?

Akeso, Inc. (9926.HK) - Overview

• Akeso's mission is to develop first‑in‑class and best‑in‑class new drugs, providing affordable therapeutic antibodies for patients worldwide.
• The company aims to integrate superior global resources to create commercial and social value, striving to become a leading global biopharmaceutical enterprise.
• Akeso focuses on addressing unmet clinical needs in major diseases such as cancer, autoimmune diseases, inflammation, and metabolic diseases.
• The company emphasizes efficient and breakthrough R&D innovation to develop novel therapeutics with global competitiveness.
• Akeso is committed to pioneering original innovation in the pharmaceutical industry, aiming to benefit patients worldwide.
• The mission reflects Akeso's dedication to advancing healthcare through innovative solutions and global collaboration.

• Global leadership in antibody therapeutics: accelerate approvals and commercial launches across China, APAC, Europe and North America.
• Pipeline diversification: expand from oncology to autoimmune, inflammation and metabolic indications with multi‑modality biologics.
• Affordability and access: scale manufacturing and partnerships to lower unit cost and broaden patient access in emerging markets.
• Open innovation: integrate global external partnerships, licensing and M&A to strengthen late‑stage assets and commercial infrastructure.

• Patient first - prioritize clinically meaningful benefit and safety for patients globally.
• Scientific excellence - pursue rigorous, mechanism‑driven R&D and original innovation.
• Integrity and compliance - maintain high ethical and regulatory standards across geographies.
• Collaboration - build global alliances with academic centers, CROs, and industry partners.
• Efficiency - streamline discovery‑to‑clinic timelines and cost structures to accelerate access.

• R&D intensity: Akeso allocates a high proportion of operating expenses to R&D to sustain first‑in‑class and best‑in‑class ambitions.
• Commercial scale-up: progressive launches and partnerships aim to convert late‑stage approvals into recurring product revenue.
• Capital strategy: access to public equity (9926.HK), licensing revenue and strategic collaborations to fund clinical development and manufacturing.
• Global footprint: clinical sites and regulatory filings expanding across Asia, Europe and North America to support global registrations.

• Advancing oncology immunotherapies from discovery through pivotal trials to deliver new options for patients with high unmet need.
• Pursuing indications beyond oncology-autoimmune and metabolic-where antibody therapeutics can offer differentiated benefit.
• Partnering with global contract manufacturers and CROs to reduce time‑to‑market and cost per patient treated.

Akeso, Inc. (9926.HK) Mission Statement

• Global leadership in antibody therapeutics with a patient‑centric focus.
• Accelerate clinical development and broaden geographic reach of programs.
• Strategic partnerships to enhance capabilities and commercial footprint.
• Attract and retain scientific, clinical, and commercial talent.
• Deliver affordable, next‑generation biologics across major therapeutic areas.

Key quantitative indicators that reflect and support Akeso's vision and strategic trajectory:

• Clinical acceleration: prioritize rapid movement of Phase I/II assets into registrational pathways and expand patient access through multi‑region trials.
• Partnership strategy: pursue alliances that are value‑accretive-co‑development, licensing, regional commercialization, and manufacturing partnerships.
• Talent & culture: recruit world‑class scientists, clinical leaders, and commercial experts while investing in ongoing training and retention programs.
• Affordability & access: optimize manufacturing and supply chain to reduce per‑unit cost and broaden patient access globally.

Strategic milestones and performance indicators Akeso tracks to realize its vision:

Akeso's vision is operationalized through measurable goals, resource allocation, and strategic partnerships, all oriented toward delivering innovative, next‑generation, and affordable antibody therapies for patients worldwide. For broader context and investor perspective, see: Exploring Akeso, Inc. Investor Profile: Who's Buying and Why?

Akeso, Inc. (9926.HK) Vision Statement

• Accountability: measurable milestones across discovery, IND filings, and pivotal trials to accelerate time-to-patient.
• Integrity: rigorous clinical governance, transparent reporting, and adherence to global regulatory standards.
• Collaboration: cross-disciplinary teamwork internally and externally with academic, clinical, and industry partners.

• Rapid clinical advancement - prioritize therapies addressing high unmet needs with streamlined trial designs and biomarker-guided cohorts.
• International expansion - scale pivotal and registration trials across APAC, North America, and Europe to broaden patient access.
• Value-accretive partnerships - pursue co-development, licensing, and commercialization collaborations to derisk programs and accelerate launch potential.
• Talent investment - recruit and retain experienced clinical, regulatory, and commercial leaders to sustain innovation velocity.
• Pipeline enrichment - continually expand and de-risk a balanced portfolio spanning immuno-oncology, targeted therapies, and novel modalities.

• Clinical acceleration: target median IND-to-Phase 2 timelines under 24 months for prioritized assets; adaptive designs to shorten go/no-go decisions.
• International footprint: establish regional clinical centers and regulatory teams to enable synchronized multi-regional development and filings.
• Partnership strategy: prioritize collaborations that deliver capital efficiency, late‑stage development expertise, or commercial reach for specific markets.
• Talent and culture: competitive equity-based incentives, career paths for scientific leaders, and cross-functional development programs to retain high performers.
• Pipeline management: maintain a balanced mix of first‑in-class and best‑in-class assets, with continuous in‑licensing and platform investment to sustain a 3-5 year clinical visibility window.